Pillars and Pitfalls of the New Pharmacovigilance Legislation: Consequences for the Identification of Adverse Drug Reactions Deriving From Abuse, Misuse, Overdose, Occupational Exposure, and Medication Errors
暂无分享,去创建一个
C. Scavone | M. Sessa | A. Capuano | C. Rafaniello | Gabriella di Mauro | A. Mascolo | Liberata Sportiello
[1] C. Scavone. Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: Results of a pharmacovigilance reporting system , 2018 .
[2] E. Clementi,et al. The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions , 2017, The Pharmacogenomics Journal.
[3] C. Scavone,et al. Campania Preventability Assessment Committee (Italy): A Focus on the Preventability of Non-steroidal Anti-inflammatory Drugs' Adverse Drug Reactions , 2017, Front. Pharmacol..
[4] E. Russo,et al. Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation , 2017, Expert opinion on drug safety.
[5] K. Taxis,et al. The Quality of Clinical Information in Adverse Drug Reaction Reports by Patients and Healthcare Professionals: A Retrospective Comparative Analysis , 2017, Drug Safety.
[6] L. Berrino,et al. Campania Region (Italy) spontaneous reporting system and preventability assessment through a case-by-case approach: a pilot study on psychotropic drugs , 2016, Expert opinion on drug safety.
[7] A. Rotondo,et al. Campania preventability assessment committee: a focus on the preventability of the contrast media adverse drug reactions , 2016, Expert opinion on drug safety.
[8] C. Torp-Pedersen,et al. Effect of Chronic Kidney Diseases on Mortality among Digoxin Users Treated for Non-Valvular Atrial Fibrillation: A Nationwide Register-Based Retrospective Cohort Study , 2016, PloS one.
[9] Ruwen Böhm,et al. OpenVigil FDA – Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications , 2016, PloS one.
[10] M. Sessa,et al. A case of figurate urticaria by etanercept , 2016, Journal of pharmacology & pharmacotherapeutics.
[11] M. Sessa,et al. Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases , 2016, Drug Safety.
[12] F. Manguso,et al. Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: Results of a pharmacovigilance reporting system. , 2016, Pharmacological research.
[13] M. Sessa,et al. Improvement of patient adverse drug reaction reporting through a community pharmacist-based intervention in the Campania region of Italy , 2014, Expert opinion on drug safety.
[14] V. Bauchau,et al. The upper bound to the Relative Reporting Ratio—a measure of the impact of the violation of hidden assumptions underlying some disproportionality methods used in signal detection , 2014, Pharmacoepidemiology and drug safety.
[15] G. Perna,et al. Unusual case of severe arrhythmia developed after acute intoxication with tosylchloramide , 2013, BMC Pharmacology and Toxicology.
[16] Chun-Mei Zhao,et al. Complexity of gastric acid secretion revealed by targeted gene disruption in mice. , 2010, Current pharmaceutical design.
[17] D. Spyker,et al. 2007 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 25th Annual Report , 2008, Clinical toxicology.
[18] E. Sellers,et al. Challenges in the Development of Prescription Opioid Abuse-deterrent Formulations , 2007, The Clinical journal of pain.
[19] G. Neale,et al. Self-harm and suicide associated with benzodiazepine usage. , 2007, The British journal of general practice : the journal of the Royal College of General Practitioners.
[20] Richard C Dart,et al. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS). , 2007, Pain medicine.
[21] C. O'brien. Benzodiazepine use, abuse, and dependence. , 2005, The Journal of clinical psychiatry.
[22] Kenneth J Rothman,et al. The reporting odds ratio and its advantages over the proportional reporting ratio , 2004, Pharmacoepidemiology and drug safety.
[23] Lehana Thabane,et al. Application of data mining techniques in pharmacovigilance. , 2003, British journal of clinical pharmacology.
[24] L P Longo,et al. Addiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives. , 2000, American family physician.
[25] R. Rinaldi,et al. Clarification and standardization of substance abuse terminology. , 1988, JAMA.
[26] Canary Wharf,et al. Guidelines on good pharmacovigilance practices (GVP) , 2012 .
[27] WHO launches Pharmacovigilance Toolkit , 2012, Reactions Weekly.
[28] M. Rawlins. Pathogenesis of adverse drug reactions , 1977 .